P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel
The possibilities of P2Y12 receptor inhibitors application in the treatment of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are discussed in the article. The results of 4 registries in which a comparative analysis of the efficacy and safety of prasu...
Main Author: | N. M. Vorobyeva |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2019-01-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/1811 |
Similar Items
-
Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes ‐ A Post‐hoc Analysis of the ISAR‐REACT 5 Trial
by: Shqipdona Lahu, et al.
Published: (2022-12-01) -
Short-term clinical outcomes of ticagrelor versus clopidogrel after percutaneous coronary intervention in patients with myocardial infarction: A randomized clinical trial study
by: Salman Nikfarjam, et al.
Published: (2023-01-01) -
Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01) -
Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01) -
Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients
by: Rebecca Gosling, et al.
Published: (2017-11-01)